Brugarolas James, Kaelin William G
Dana-Farber Cancer Institute and Harvard Medical School, Howard Hughes Medical Institute, 44 Binney Street, Mayer 457, Boston, Massachusetts 02115, USA.
Cancer Cell. 2004 Jul;6(1):7-10. doi: 10.1016/j.ccr.2004.06.020.
The LKB1 tumor suppressor protein controls the activity of the TSC1/TSC2 tumor suppressor complex. Mutations in LKB1 cause Peutz-Jeghers syndrome (PJS), and mutations in either TSC1 or TSC2 cause tuberous sclerosis complex--two syndromes characterized by the development of hamartomas. LKB1 activation by energy deprivation activates AMPK, which in turn phosphorylates and activates TSC2. TSC2 activation results in the inactivation of mTOR, a critical regulator of protein translation. How mTOR dysregulation after inactivation of LKB1 or TSC1/2 contributes to hamartoma development is not known. However, hypoxia-inducible factor (HIF) and VEGF are regulated by mTOR and are likely to play a contributory role.
LKB1肿瘤抑制蛋白控制TSC1/TSC2肿瘤抑制复合物的活性。LKB1突变导致黑斑息肉综合征(PJS),TSC1或TSC2的突变导致结节性硬化症——这两种综合征的特征是错构瘤的形成。能量剥夺激活LKB1进而激活AMPK,AMPK反过来磷酸化并激活TSC2。TSC2的激活导致mTOR失活,mTOR是蛋白质翻译的关键调节因子。LKB1或TSC1/2失活后mTOR失调如何导致错构瘤的形成尚不清楚。然而,缺氧诱导因子(HIF)和血管内皮生长因子(VEGF)受mTOR调节,可能起一定作用。